18889881171
Kalkine 0
countryflagUS

McKesson Corporation

Healthcare US MCK

730.095USD
-0.705(0.10%)

Last update at 2025-06-13T16:59:00Z

Day Range

724.80732.99
LowHigh

52 Week Range

330.35476.35
LowHigh

Fundamentals

  • Previous Close 730.80
  • Market Cap60436.76M
  • Volume179328
  • P/E Ratio17.95
  • Dividend Yield0.55%
  • EBITDA4897.00M
  • Revenue TTM291098.00M
  • Revenue Per Share TTM2130.24
  • Gross Profit TTM 12358.00M
  • Diluted EPS TTM25.30

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax 4630.00M 1928.00M -5034.00000M 1144.00M 610.00M
Minority interest 162.00M -173.00000M 199.00M 220.00M 221.00M
Net income 3560.00M 1114.00M -4339.00000M 900.00M 34.00M
Selling general administrative 15552.00M 21074.00M 17698.00M 18336.00M 8403.00M
Selling and marketing expenses -7776.00000M -10537.00000M -8849.00000M -9168.00000M 8403.00M
Gross profit 12358.00M 13130.00M 12148.00M 12023.00M 11754.00M
Reconciled depreciation 608.00M 760.00M 887.00M 922.00M 949.00M
Ebit 4381.00M 2852.00M 3522.00M 1663.00M 3268.00M
Ebitda 5687.00M 3612.00M 4409.00M 2585.00M 4217.00M
Depreciation and amortization 1306.00M 760.00M 887.00M 922.00M 949.00M
Non operating income net other 497.00M 68.00M 223.00M 12.00M -12.00000M
Operating income 4381.00M 2852.00M 3522.00M 1663.00M 886.00M
Other operating expenses 272129.00M 261373.00M 234929.00M 228292.00M 211039.00M
Interest expense 248.00M 178.00M 217.00M 249.00M 264.00M
Tax provision 905.00M 636.00M -695.00000M 18.00M 356.00M
Interest income 248.00M 10.00M 217.00M 49.00M 39.00M
Net interest income -248.00000M -178.00000M -217.00000M -200.00000M -225.00000M
Extraordinary items -3.00000M -5.00000M -1.00000M -6.00000M 87.00M
Non recurring -8.00000M 274.00M 8339.00M 270.00M 2394.00M
Other items - - - - -
Income tax expense 905.00M 636.00M -695.00000M 18.00M 356.00M
Total revenue 276711.00M 263966.00M 238228.00M 231051.00M 214319.00M
Total operating expenses 7776.00M 10537.00M 8849.00M 9264.00M 8474.00M
Cost of revenue 264353.00M 250836.00M 226080.00M 219028.00M 202565.00M
Total other income expense net 249.00M -924.00000M -8556.00000M -519.00000M -2406.00000M
Discontinued operations -3.00000M -5.00000M -1.00000M -6.00000M 1.00M
Net income from continuing ops 3725.00M 1292.00M -4339.00000M 1126.00M 254.00M
Net income applicable to common shares 3560.00M 1114.00M -4539.00000M 900.00M 34.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 62320.00M 63298.00M 65015.00M 61247.00M 59672.00M
Intangible assets 2277.00M 2059.00M 2878.00M 3156.00M 3689.00M
Earning assets - - - - -
Other current assets 496.00M 5414.00M 665.00M 617.00M 529.00M
Total liab 63810.00M 65090.00M 63569.00M 54536.00M 49992.00M
Total stockholder equity -1857.00000M -2272.00000M -21.00000M 5092.00M 8094.00M
Deferred long term liab 1387.00M 1418.00M 1411.00M 2255.00M 2998.00M
Other current liab 4200.00M 9284.00M 9.00M 683.00M 3443.00M
Common stock 3.00M 2.00M 2.00M 2.00M 3.00M
Capital stock 3.00M 2.00M 2.00M 2.00M 3.00M
Retained earnings 12295.00M 9030.00M 8202.00M 13022.00M 12409.00M
Other liab 9808.00M 10142.00M 11193.00M 3917.00M 5068.00M
Good will 9947.00M 9451.00M 9493.00M 9360.00M 9358.00M
Other assets 1755.00M 1251.00M 2581.00M 1858.00M 1705.00M
Cash 4678.00M 3532.00M 6278.00M 4015.00M 2981.00M
Cash and equivalents 4678.00M 3532.00M 6278.00M 4015.00M 2981.00M
Total current liabilities 47957.00M 48466.00M 44103.00M 42624.00M 37626.00M
Current deferred revenue - - 3987.00M 3340.00M -
Net debt 2617.00M 4010.00M 3127.00M 5386.00M 4614.00M
Short term debt 1267.00M 1096.00M 1132.00M 1406.00M 330.00M
Short long term debt 968.00M 799.00M 742.00M 1052.00M 330.00M
Short long term debt total 7295.00M 7542.00M 9405.00M 9401.00M 7595.00M
Other stockholder equity -13250.00000M -9770.00000M -6745.00000M -6229.00000M -2469.00000M
Property plant equipment 2177.00M 2092.00M 2581.00M 2365.00M 2548.00M
Total current assets 44292.00M 46231.00M 45382.00M 42222.00M 38465.00M
Long term investments - - - 0.00000M 3513.00M
Net tangible assets -12679.00000M -12416.00000M -9254.00000M -4362.00000M -3560.00000M
Short term investments - - - - -
Net receivables 19410.00M 18583.00M 19181.00M 19950.00M 18246.00M
Long term debt 4626.00M 5080.00M 6406.00M 6335.00M 7265.00M
Inventory 19691.00M 18702.00M 19246.00M 16734.00M 16709.00M
Accounts payable 42490.00M 38086.00M 38975.00M 37195.00M 33853.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 367.00M 480.00M 196.00M 217.00M 193.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -905.00000M -1534.00000M -1480.00000M -1703.00000M -1849.00000M
Additional paid in capital - - - - -
Common stock total equity 3.00M 2.00M 2.00M 2.00M 3.00M
Preferred stock total equity - - - - -
Retained earnings total equity 12295.00M 9030.00M 8202.00M 13022.00M 12409.00M
Treasury stock - -17045.00000M -13670.00000M -12892.00000M -8902.00000M
Accumulated amortization - - - - -
Non currrent assets other 1992.00M 1917.00M 2581.00M 2258.00M 2099.00M
Deferred long term asset charges - - - - -
Non current assets total 18028.00M 17067.00M 19633.00M 19025.00M 21207.00M
Capital lease obligations 1701.00M 1663.00M 2257.00M 2014.00M -
Long term debt total 4626.00M 5080.00M 6406.00M 6335.00M 7265.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -542.00000M -89.00000M 400.00M 37.00M -1381.00000M
Change to liabilities 4151.00M 3045.00M 1101.00M 3944.00M 1881.00M
Total cashflows from investing activities -542.00000M -89.00000M -415.00000M -579.00000M -1381.00000M
Net borrowings -277.00000M -1334.00000M -540.00000M -298.00000M -16.00000M
Total cash from financing activities -4368.00000M -6321.00000M -1693.00000M -2734.00000M -2227.00000M
Change to operating activities -1370.00000M 49.00M 8216.00M -377.00000M -377.00000M
Net income 3722.00M 1287.00M -4340.00000M 1120.00M 255.00M
Change in cash 743.00M -2461.00000M 2373.00M 1042.00M 309.00M
Begin period cash flow 3935.00M 6396.00M 4023.00M 2981.00M 2672.00M
End period cash flow 4678.00M 3935.00M 6396.00M 4023.00M 2981.00M
Total cash from operating activities 5159.00M 4434.00M 4542.00M 4374.00M 4036.00M
Issuance of capital stock 163.00M 220.00M 92.00M 113.00M 75.00M
Depreciation 608.00M 760.00M 887.00M 922.00M 949.00M
Other cashflows from investing activities -152.00000M 299.00M -364.00000M -254.00000M -955.00000M
Dividends paid -292.00000M -277.00000M -276.00000M -294.00000M 292.00M
Change to inventory -1259.00000M -1169.00000M -2276.00000M -376.00000M -368.00000M
Change to account receivables -1082.00000M -1843.00000M 1145.00M -2494.00000M -967.00000M
Sale purchase of stock -3638.00000M -3516.00000M -770.00000M -1954.00000M -1639.00000M
Other cashflows from financing activities 9123.00M 10092.00M 6624.00M 21136.00M 38009.00M
Change to netincome 140.00M 2064.00M -525.00000M 193.00M 2304.00M
Capital expenditures 558.00M 535.00M 641.00M 506.00M 557.00M
Change receivables -1082.00000M -1843.00000M 1145.00M -2494.00000M -967.00000M
Cash flows other operating -1121.00000M 290.00M 8550.00M 1065.00M 68.00M
Exchange rate changes - - - - -
Cash and cash equivalents changes 249.00M -1976.00000M 2434.00M 1061.00M 428.00M
Change in working capital 384.00M 82.00M 8186.00M 689.00M 546.00M
Stock based compensation - - 233.00M 1223.00M 2273.00M
Other non cash items 465.00M 2271.00M 484.00M 762.00M -176.00000M
Free cash flow 4601.00M 3899.00M 3901.00M 3868.00M 3479.00M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MCK
McKesson Corporation		 -0.705 0.10% 730.10 17.95 14.53 0.20 5.04 0.22 12.17
COR
Cencora Inc.		 0.94 0.32% 295.98 23.39 - - -
CAH
Cardinal Health Inc		 1.94 1.21% 162.46 166.11 14.71 0.12 16.07 0.12 19.78
HSIC
Henry Schein Inc		 -0.78 1.10% 70.30 24.12 14.04 0.74 2.50 0.95 13.33
SHTDY
SINOPHARM GROUP CO LTD ADR		 0.21 1.75% 12.21 6.18 7.49 0.01 0.76 0.03 0.72

Reports Covered

Stock Research & News

View All

Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Corporation

6555 State Highway 161, Irving, TX, United States, 75039

Key Executives

Name Title Year Born
Mr. Brian S. Tyler Ph.D. CEO & Director 1967
Mr. Britt J. Vitalone Exec. VP & CFO 1969
Ms. Nancy Avila Exec. VP, Chief Information Officer & CTO 1967
Ms. Lori A. Schechter J.D. Exec. VP, Chief Legal Officer & Gen. Counsel 1962
Mr. Napoleon B. Rutledge Jr. Sr. VP, Controller & Chief Accounting Officer 1972
Ms. Holly Weiss Sr. VP of Investor Relations NA
Mr. Pete Slone Sr. VP of Corp. Public Affairs NA
Ms. LeAnn B. Smith Exec. VP & Chief HR Officer NA
Mr. Kirk Kaminsky Pres of The US Pharmaceutical & Specialty Solutions Bus. NA
Paul A. Smith Sr. VP of Taxes NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.